XoLacta adjuvant therapy to reduce radiation side effects during HER2-positive breast cancer treatment
Official title: XoLacta: An Adjuvant Therapy for treatment of Radiation Side effects during HER2-Positive Breast Cancer Treatment
Funded at Tiny Cargo Company, the · NIH-11413717 · Data updated 2026-11-12
A new milk-derived therapy called XoLacta aims to lessen radiation-related side effects for people undergoing treatment for HER2-positive breast cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tiny Cargo Company, the NIH-funded |
| Lab location | 1 site (Roanoke, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,022,907 |
| NIH project number | 5R44CA272078-03 |
| Project ID | NIH-11413717 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women with HER2-positive breast cancer undergoing radiotherapy who may benefit from an adjuvant radiotherapeutic approach.
✕Less likely to help
Patients not receiving radiotherapy or those for whom XoLacta is not suitable due to medical reasons or contraindications.
What this research studies
This project tests XoLacta, a milk extracellular vesicle therapy loaded with a drug, as an adjuvant to radiotherapy in breast cancer care. It builds on prior Phase I work and plans to use animal models and translational studies to support safety, dosing, and delivery in irradiated tissues. The work includes plans to scale production, study pharmacokinetics and ADME, and collaborate with a U.S. military research institute to characterize performance. The goal is to enable a practical, orally available treatment that can be integrated with standard radiotherapy to promote healing after radiation exposure.
Why it matters
Potential benefit: If successful, patients could experience fewer radiation-related side effects and improved healing during cancer treatment.
How similar studies have gone: Previous Phase I work supports the concept; this grant extends toward larger-scale safety, dosing, and manufacturing studies.
Where this research is happening
-
Tiny Cargo Company, the
Roanoke, United States Active
Researchers
- Principal investigator: Marsh, Spencer Reid — Tiny Cargo Company, the
- Study coordinator: Marsh, Spencer Reid
Related research
Other NIH-funded projects on the same topics.
-
XoLacta to reduce radiation side effects in HER2-positive breast cancer
XoLacta, a milk-derived therapy given during radiation, aims to help people with HER2-positive breast cancer heal better and have fewer side effects.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Prolactin signaling and brain metastasis in HER2-positive breast cancer
Researchers are studying how prolactin signals help HER2-positive breast cancer cells grow in the brain, with the goal of finding new ideas to prevent brain metastases.
-
Ig repertoire in tumor-infiltrating B cells in metastatic HER2-positive breast cancer (mouse model)
Scientists will study how antibodies from immune cells inside HER2-positive breast tumors behave in a mouse model to understand potential new ways to fight the cancer.
-
Autophagy and vesicle trafficking linked to HER2+ breast cancer progression
A cancer research project aims to understand how cell recycling processes and vesicle movement affect HER2-positive breast cancer, with potential implications for metastasis and resistance to therapy.
-
Why some HER2-positive breast cancers survive targeted therapy
This project looks for the specific cancer cells that survive HER2-targeted drugs in people with HER2-positive breast cancer to find ways to stop drug resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.